Human milk oligosaccharide supplementation in irritable bowel syndrome patients: A parallel, randomized, double-blind, placebo-controlled study.

Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society
Cristina IribarrenMagnus Simrén

Abstract

Human milk oligosaccharides safely and beneficially impact bifidobacteria abundance in healthy adults, while their effects in patients with irritable bowel syndrome (IBS) are unknown. Hence, we aimed to determine the dose of 4:1 mix of 2'-O-fucosyllactose and Lacto-N-neotetraose (2'FL/LNnT) that increases fecal bifidobacteria abundance without aggravating overall gastrointestinal symptoms in IBS patients in a randomized, double-blind, controlled study. Additionally, the impact of 2'FL/LNnT on the fecal bacterial profile was assessed. Irritable bowel syndrome patients diagnosed according to the Rome IV criteria received placebo (glucose), or 5 g or 10 g 2'FL/LNnT for 4 weeks followed by a four-week follow-up period. Gastrointestinal Symptom Rating Scale-IBS was used to assess gastrointestinal symptom severity; fecal microbiota composition was evaluated by GA-map™ Dysbiosis Test. Of the included 60 patients, two (one placebo and one 10 g) discontinued prematurely. Fecal bifidobacteria abundance was increased at week 4, but not at week 8, in the 10 g group compared to the other groups. Severity of overall or individual gastrointestinal symptoms did not differ between the groups at week 4 or 8, and no symptom deterioration was seen...Continue Reading

References

Jul 1, 1994·Journal of Clinical Gastroenterology·K W Heaton, L J O'Donnell
Jul 8, 1999·The Journal of Nutrition·J O HunterA J Lee
Jun 6, 2000·The American Journal of Clinical Nutrition·M B EngferH Daniel
Feb 8, 2002·Journal of Psychosomatic Research·Ingvar BjellandDag Neckelmann
Jun 29, 2002·The British Journal of Nutrition·S KolidaG R Gibson
Oct 9, 2003·Scandinavian Journal of Gastroenterology·I K WiklundJ Naesdal
Jun 6, 2006·Applied and Environmental Microbiology·Robert E WardJ Bruce German
Nov 11, 2011·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·G C ParkesJ D Sanderson
Apr 1, 2015·Nature Reviews. Gastroenterology & Hepatology·Laure B BindelsJens Walter
Apr 29, 2015·Gut and Liver·Sean M P BennetMagnus Simren
Sep 17, 2015·Early Human Development·Lars Bode
Nov 27, 2015·Microbiology and Molecular Biology Reviews : MMBR·Essaid Ait BarkaGilles P van Wezel
May 5, 2016·Gastroenterology·Fermín MearinRobin Spiller
May 10, 2016·Nature Reviews. Disease Primers·Paul EnckRobin C Spiller
Jan 20, 2017·Annals of Nutrition & Metabolism·Sharon M Donovan, Sarah S Comstock
Apr 19, 2017·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·M MegoF Azpiroz
Aug 7, 2017·Journal of Dairy Science·Taksawan ThongaramMichael J Miller
Mar 3, 2018·Advances in Therapy·Bruno K Rodiño-JaneiroJavier Santos
Jul 3, 2018·Gastroenterology·Jose-Walter HuamanFernando Azpiroz
Jul 22, 2018·F1000Research·Stacy Menees, William Chey
Oct 20, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Sean AustinBegoña Casado
Apr 4, 2019·Gastroenterology·Rapat PittayanonPaul Moayyedi
Nov 30, 2017·Emerging Topics in Life Sciences·Ian O'NeillLindsay J Hall

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriotherapy (ASM)

Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.

Bacteriotherapy

Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.